Despite their demonstrated efficacy in melanoma, lung cancer, lymphoma, and hepatocellular carcinoma (110), PD-1/PD-L1 checkpoint inhibitors continue to show limited effectiveness in PCa. This evidence concerns the gene PDCD1 and lymphoma.